MANKIND PHARMA
Back to Balance Sheet
|
MANKIND PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹89 Cr | ₹48 Cr | ₹83 Cr | ₹35 Cr | ₹242 Cr |
What is the latest Contingent Liabilities ratio of MANKIND PHARMA ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹89 Cr |
Mar2023 | ₹48 Cr |
Mar2022 | ₹83 Cr |
Mar2021 | ₹35 Cr |
Mar2020 | ₹242 Cr |
How is Contingent Liabilities of MANKIND PHARMA Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹89 Cr | 85.77 | |
Mar2023 | ₹48 Cr | -41.97 | |
Mar2022 | ₹83 Cr | 137.32 | |
Mar2021 | ₹35 Cr | -85.60 | |
Mar2020 | ₹242 Cr | - |
Compare Contingent Liabilities of peers of MANKIND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MANKIND PHARMA | ₹106,888.2 Cr | -11.2% | -2.3% | 33.6% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹424,382.0 Cr | -5.8% | -3.2% | 35.1% | Stock Analytics | |
DIVIS LABORATORIES | ₹159,224.0 Cr | -2.8% | -3.6% | 44.7% | Stock Analytics | |
CIPLA | ₹116,943.0 Cr | -3.9% | -0.5% | 13.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹111,588.0 Cr | -1.2% | 7.1% | 17.8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,704.0 Cr | -2.7% | -0.1% | 40.9% | Stock Analytics |
MANKIND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | -11.2% |
-2.3% |
33.6% |
SENSEX | -2.1% |
-6.4% |
7% |
You may also like the below Video Courses